NasdaqCM - Delayed Quote USD
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
At close: November 6 at 4:00 PM EST
After hours: November 6 at 5:52 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
37,235.0490
39,503.6360
28,228.7580
10,104.5130
2,434.6510
Operating Income
-37,235.0490
-39,503.6360
-28,228.7580
-10,104.5130
-2,434.6510
Net Non Operating Interest Income Expense
521.3550
498.9640
182.8020
-2.4140
-1,347.9370
Other Income Expense
741.2830
-239.2160
-194.7090
1,591.0550
--
Pretax Income
-35,972.4110
-39,243.8880
-28,240.6650
-8,515.8720
-3,782.5880
Tax Provision
22.3160
16.9490
20.7770
6.0040
0.8000
Net Income Common Stockholders
-35,994.7270
-39,260.8370
-28,261.4420
-8,521.8760
-3,783.3880
Diluted NI Available to Com Stockholders
-35,994.7270
-39,260.8370
-28,261.4420
-8,521.8760
-3,783.3880
Basic EPS
-1.32
-1.65
-1.25
-0.58
-1.24
Diluted EPS
-1.32
-1.65
-1.25
-0.58
-1.24
Basic Average Shares
27,840.8620
23,798.2030
19,516.4790
14,790.8430
3,061.6700
Diluted Average Shares
27,840.8620
23,798.2030
19,516.4790
14,790.8430
3,061.6700
Total Operating Income as Reported
-37,235.0490
-39,503.6360
-28,228.7580
-10,104.5130
-2,434.6510
Total Expenses
37,235.0490
39,503.6360
28,228.7580
10,104.5130
2,434.6510
Net Income from Continuing & Discontinued Operation
-35,994.7270
-39,260.8370
-28,261.4420
-8,521.8760
-3,783.3880
Normalized Income
-36,675.9322
-39,071.8564
-28,107.6219
-9,683.3462
-3,783.3880
Interest Income
509.5810
498.9640
182.8020
--
105.1830
Interest Expense
--
--
--
2.4140
1,453.1200
Net Interest Income
521.3550
498.9640
182.8020
-2.4140
-1,347.9370
EBIT
-36,243.9330
-39,503.6360
-28,228.7580
-8,513.4580
-2,329.4680
EBITDA
-36,243.9330
-39,503.6360
-28,228.7580
-8,513.4580
-2,328.8770
Reconciled Depreciation
--
--
--
--
0.5910
Net Income from Continuing Operation Net Minority Interest
-35,994.7270
-39,260.8370
-28,261.4420
-8,521.8760
-3,783.3880
Total Unusual Items Excluding Goodwill
862.2850
-239.2160
-194.7090
1,591.0550
--
Total Unusual Items
862.2850
-239.2160
-194.7090
1,591.0550
--
Normalized EBITDA
-37,106.2180
-39,264.4200
-28,034.0490
-10,104.5130
-2,328.8770
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
181.0799
-50.2354
-40.8889
429.5848
--
12/31/2020 - 10/18/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
EYEN Eyenovia, Inc.
0.5002
-1.50%
CRDF Cardiff Oncology, Inc.
3.8100
+3.25%
SLS SELLAS Life Sciences Group, Inc.
1.1600
-1.69%
AXSM Axsome Therapeutics, Inc.
90.97
+1.94%
TERN Terns Pharmaceuticals, Inc.
7.24
+0.98%
RNAZ TransCode Therapeutics, Inc.
0.4690
-7.46%
NRXP NRx Pharmaceuticals, Inc.
1.3100
+3.15%
UNCY Unicycive Therapeutics, Inc.
0.5020
+1.46%
ATRA Atara Biotherapeutics, Inc.
10.01
-2.68%
MESO Mesoblast Limited
8.73
-0.46%